<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The aim of this study was to investigate the diagnostic and prognostic significance of the methylation status of secreted frizzled-related protein 2 (SFRP2) in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Methylation-specific PCR assay was performed to analyze SFRP2 promoter methylation in solid tissue, stool and serum samples collected from 169 CRC patients, 63 patients with advanced <z:mpath ids='MPATH_270'>adenomas</z:mpath>, 46 patients with non-<z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath> and 30 <z:mpath ids='MPATH_458'>normal</z:mpath> healthy controls </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Methylated SFRP2 was frequently detected in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues and <z:e sem="disease" ids="C0940937" disease_type="Neoplastic Process" abbrv="">precancerous lesions</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The sensitivity of SFRP2 methylation levels in tissue, fecal and serum DNA for the detection of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> was similar, ranging from 66.9 to 88.2%; however, serum SFRP2 methylation levels showed a markedly higher specificity in discriminating <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> from benign <z:mpath ids='MPATH_270'>adenomas</z:mpath> than those of SFRP2 methylation levels in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and fecal DNA </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, serum SFRP2 methylation was significantly associated with poor differentiation grade (P=0.019), serosal/subserosal invasion (P &lt; 0.001), lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> status (P &lt; 0.001) and TNM stage (P &lt; 0.001) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with SFRP2 hypermethylation in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, stool and serum samples had a significantly shorter overall survival than those negative for SFRP2 methylation (P=0.0216, 0.0219, and 0.0255, respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>Multivariate Cox regression analysis revealed that SFRP2 promoter methylation in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples was an independent prognostic factor for overall survival </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: Our data suggest that serum SFRP2 methylation status represents a promising, non-invasive marker for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> detection and staging </plain></SENT>
<SENT sid="8" pm="."><plain>Hypermethylated SFRP2 may have prognostic relevance in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>